CRISPR and CRISPR-Associated Gene Market Size, Growth Drivers and Global Forecast 2035 | At a Thriving CAGR of 13.88%

Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress

ALAMEDA, Calif.--(BUSINESS WIRE)--Apr 23, 2025-

The State of CRISPR and Genome Editing

REGISTER NOWBroadcast Date: Wednesday, June 11, 2025Time: 8:00 am PT, 11:00 am ET, 17:00 CESTIt has been 20 years since the term “genome editing” first entered the scientific lexicon, a field that was revolutionized by the development of CRISPR gene editing in 2012. But the remarkable pace of progress in the first decade has hit some headwinds of late. In particular, the use of CRISPR as a clinical tool has progressed more slowly than anticipate…

AAV-CRISPR Targets PD-L1 for Ovarian Cancer

In a groundbreaking advancement in ovarian cancer therapeutics, researchers have unveiled a pioneering gene immunotherapy approach leveraging adeno-associated virus (AAV) vectors combined with CRISPR/Cas9 genome editing technology to directly target and disrupt PD-L1 expression within tumor cells. This innovative strategy addresses the persistent challenges faced by conventional antibody therapies aimed at immune checkpoint molecules, which have…

CRISPR and CRISPR-Associated Gene Market Size, Growth Drivers and Global Forecast 2035 | At a Thriving CAGR of 13.88%

Biomedical Research leads at USD 1.5 billion, supporting genetic discovery and translational research. US, NY, UNITED STATES, April 22, 2025 /EINPresswire.com/ -- CRISPR and CRISPR-Associated Gene Market Set to Surge to $20 Billion by 2035, Fueled by Technological Breakthroughs and Biotech Investments The global CRISPR and CRISPR-Associated Gene Market Size is poised for exponential growth, rising from USD 4.79 billion in 2024 to an estimated US…